恶性肠梗阻营养制剂的选择

doi:10.16689/j.cnki.cn11-9349/r.2020.03.023

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1084 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要晚期恶性肿瘤合并恶性肠梗阻（MBO）的发生率为5%～43%。MBO的常规治疗方法有药物治疗、手术治疗、营养治疗、支架置入、胃肠减压及中医治疗。但是，由于消化道梗阻的存在，大多数MBO患者无法进食或仅能进食少量食物，尽早予以营养治疗，对于提高患者生存质量、延长生存期非常重要。只要肠道有功能，就尽量采用肠内营养。营养不良治疗的基本原则应该是满足患者能量需求、蛋白质需求、液体量目标需求及微量营养素需要量。营养治疗主要采用第四阶梯部分肠内营养+部分肠外营养（PEN+PPN）或第五阶梯全肠外营养（TPN）。本文就患者可使用的肠内营养制剂类型及肠外营养制剂类型进行分别阐述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孙洁
	姚颖

Abstract：The incidence of malignant bowel obstruction (MBO) in advanced tumors is about 5%-43%. The routine treatment methods of MBO include operation, medicine, nutrition therapy, gastrointestinal decompression, stent placement and traditional Chinese medicine. Due to the presence of digestive tract obstruction, most MBO patients are unable to eat or can only eat a small amount of food. As long as the gut is functioning, try to use enteral nutrition.The basic principle for the treatment of malnutrition should be to meet the patients energy needs“protein needs” fluid requirements and micronutrient requirements. Early nutritional therapy is very important for improving the quality of life and prolonging the survival period. Partial enteral nutrition (PEN)+ partial parenteral nutrition (PPN) or total parenteral nutrition (TPN) were mainly used for nutritional treatment. The types of enteral nutrition preparations and parenteral nutrition preparations that can be used by MBO patients were described in this paper.

基金资助:国家自然科学基金项目 (81770684)
国家自然科学基金项目（81974087）
开同CKD基金（KETO-036-INC）

通讯作者: 姚颖；电子邮箱：yaoyingkk@126.com

引用本文:

孙洁，姚颖. 恶性肠梗阻营养制剂的选择[J]. 肿瘤代谢与营养电子杂志, 2020, 7(3): 371-374.
Sun Jie,Yao Ying. Nutritional preparations for malignant bowel obstruction. Electron J Metab Nutr Cancer, 2020, 7(3): 371-374.

1.HSU J, SEVAK S.Management of malignant large-bowel obstruction［J］.Diseases of the Colon & Rectum, 2019, 62(9):1028-1030.
2.LEGENDRE H, Vanhuyse F, Caroli-Bosc F X, et al. Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction［J］. Eur J Surg Oncol, 2001, 27(4):364-367.
3.BERGER J, LESTER P, RODRIGUES L. Medical therapy of malignant bowel obstruction with octreotide, dexamethasone, and metoclopramide［J］.Am J Hosp Palliat Care, 2016, 33(4):407-410.
4.石汉平, 许红霞等.营养不良的五阶梯治疗［J］.肿瘤代谢与营养电子杂志, 2015, 2(1):29-33.
5.中国抗癌协会.肿瘤营养治疗通则［J］.肿瘤代谢与营养电子杂志, 2016, 3(1):34-39.
6.中华医学会肠外肠内营养学分会.肿瘤患者营养支持指南［J］.中华外科杂志, 2017, 55(11):801-829.
7.蒋朱明, 于康.为什么要研讨肠内营养制剂的分类［J］.临床外科杂志, 2004, 12(5):263-264.
8.LUBOS S.临床营养基础［M］.上海: 复旦大学出版社, 2007:230-240.
9.MAGNUSON B L, CLIFFORD T M, HOSKINS L A, et al. Enteral nutrition and drug administration,interactions,and complications［J］.Nutr Clin Pract, 2005, 20(6):618-624.
10.ARENDS J, BACHMANN P, BARACOS V, et al.ESPEN guidelines on nutrition in cancer patients［J］. Clin Nutr, 2017, 36(1):11-48.
11.Singer P, Blaser A R, Berger M M, et al.ESPEN guideline on clinical nutrition in the intensive care unit［J］.Clin Nutr, 2019, 38(1):48-79.
12.GOMES F, SCHUETZ P, BOUNOURE L, et al.ESPEN guidelines on nutritional support for polymorbid internal medicine patients ［J］.Clin Nutr, 2018, 37(1):336-353.
13.YAN S, LI M, YANG D, et al.Associations between omega-3 fatty acid supplementation and anti-inflammatory effects in patients with digestive system cancer: A meta-analysis［J］.Nutr Cancer, 2020, 72(7):1098-1114.
14.ARENDS J, BACHMANN P, BARACOS V, et al.ESPEN guidelines on nutrition in cancer patients ［J］.Clin Nutr, 2017, 36(1):11-48.
15.McCLAVE S A, DIBAISE J K, MULLIN G E, et al.ACG clinical guideline: Nutrition therapy in the adult hospitalized patient［J］.Am J Gastroenterol, 2016, 111(3):315-334.
16.WEIMAIM A, BRAGA M, CARLI F, et al.ESPEN guideline: Clinical nutrition in surgery［J］.Clin Nutr, 2017, 36(3):623-650.
17.BOZZETTI F.The role of parenteral nutrition in patients with malignant bowel obstruction［J］.Support Care Cancer, 2019, 27(12):4393-4399.
18.CHOUHAN J, GUPTA R, ENSOR J, et al. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction［J］.Cancer Med, 2016, 5(2):239-247.
19.HASENBERG T, ESSENBREIS M, HEROLD A, et al.Retracted: Early supplementation of parenteral nutrition is capable of improving quality of life,chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: Results from a prospective,randomized clinical trial［J］.Colorectal Disease, 2010, 12(10Online):e190-e199.
20.SHANG E, WEISS C, POST S, et al.Retraction: The influence of early supplementation of parenteral nutrition on quality of life and body composition in patients with advanced cancer［J］.JPEN J Parenter Enteral Nutr, 2006, 30(3):222-230.
21.CADENA AJ, HABIB S, RINCON F,et al.The benefits of parenteral nutrition (pn) versus enteral nutrition (en) among adult critically ill patients: What is the evidence? A literature review［J］.J Intensive Care Med, 2020, 35(7):615-626.
22.NEJATINAMINI S, KUBRAK C, LVAREZ-CAMACHO M, et al. Head and neck cancer patients do not meet recommended intakes of micronutrients without consuming fortified products［J］.Nutr Cancer, 2018, 70(3):474-482.